Intuitive Surgical, Inc. (ISRG) Analyst Ratings & Price Targets

Intuitive Surgical, Inc.

ISRG · Nasdaq

Analyst Consensus

Buy

24 analysts

$392

Current

$590

Low

$484

Average

$590

High

Average target implies +23.47% versus the current price.

Analyst Ratings Synthesis

The consensus is Buy across 24 analysts, with a stated mean price target of $484; consensus low and high targets are not provided. The named targets cluster around $454 to $520.95, including Leerink at $454, MarketBeat's reported $509.02 and Public.com's $520.95, while Citigroup's $590 is the most bullish named target. Leerink is least bullish among the named firms and cut its target from $573 to $454 after the second-quarter earnings. The direction of documented recent revisions is therefore lower, although Citigroup's March upgrade was positive. The substantive disagreement centers on future revenue growth, expansion beyond urology, discount rates and terminal earnings multiples.

Rating Actions

1 firm captured

Firm	Analyst	Rating	Price Target	Upside	Date	Source
Citigroup	—	Unrated Upgraded and raised price target	$590	+50.5%	Mar 11, 2026	Open the report this row came from

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

BTIG

CITIGROUP

DEUTSCHE BK SEC

EVERCORE ISI

HSBC GLOBAL RES

JEFFERIES & CO.

JP MORGAN SECUR

LEERINK PARTNRS

MIZUHO SECURITI

MORGAN STANLEY

OPPENHEIMER HLD

PIPER SANDLER

RAYMOND JAMES

RBC CAPITAL

SANFORD BERNSTE

STIFEL NICOLAUS

TRUIST SECURITI

UBS

WELLS FARGO SEC

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: ISRG
Type: Stock
Sector: Health Care
Industry: Industrial Specialties
Exchange: Nasdaq

Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.

Key Issues

Bullish view

General surgery and newer specialties are gaining traction, giving Intuitive Surgical additional procedure opportunities beyond its established urology base. Broader adoption could create fresh avenues for long-term procedure growth.

Bearish view

The supplied evidence identifies expansion as an opportunity but does not establish its scale or adoption pace. If newer specialties remain smaller or slower to develop, the expected diversification may not materially offset more mature areas.

Analyst Consensus

See all

Buy

24 analysts

$392

Current

$590

Low

$484

Average

$590

High

Average target implies +23.47% versus the current price.

Earnings History

BeatMissNo estimate

Intuitive Surgical, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers